Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up

Congress : ESMO

Authors : Karim Fizazi, Alexandra Carmel, Florence Joly, Remy Delva, Gwenaëlle Gravis, Frederic Rolland, Frank Priou, Jean-Marc Ferrero, Nadine Houede, Loïc Mourey, Christine Theodore, Ivan Krakowski, Jean-François Berdah, Marjorie Baciuchka, Brigitte Laguerre, Aude Fléchon, Alain Ravaud, Meryem Brihoum, Stephane Culine, Gwénaël Le Teuff.

Experts group or program : Groupe d’étude des tumeurs urogénitales (GETUG)

GETUG-12 assessed docetaxel-estramustine in patients with high-risk localized prostate cancer: the primary endpoint of relapse-free survival (RFS) was met (adjusted HR: 0.71 [95% CI: 0.54-0.94], p = 0.017) (Lancet Oncol 2015; 16: 787-94). This analysis updates RFS and assesses clinical events for the first time.

En savoir plus